Generic Name and Formulations:
Erythromycin 3%, benzoyl peroxide 5%; gel.
Cutanea Life Sciences, Inc.
Indications for AKTIPAK:
Contents must be mixed (in the palm of the hand) prior to use. Apply to cleansed, dried areas twice daily.
Avoid eyes, mouth, mucous membranes. Discontinue if excessive irritation occurs. Avoid excessive or prolonged exposure to sunlight. Flammable. Pregnancy (Cat.C). Nursing mothers.
Additive irritation with peeling, desquamating, abrasive agents. Concomitant other topical acne products: not recommended.
Macrolide antibiotic + antibacterial/ keratolytic.
Dry skin, application site reactions (eg, stinging, erythema, burning), blepharitis, pruritus, photosensitivity, peeling, superinfection; may bleach hair or fabrics.
Gel (dual-chamber pouches, mixed by patient)—60
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma